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Telomeres are nucleoprotein complexes at chromosome ends that shorten with each cell division and play key roles in maintaining chromosomal integrity1. Telomere length (TL) is 
heritable, but there is incomplete understanding of its genetic deter-
mination2–4. Extreme shortening of telomeres, due to rare mutations 
in telomere regulatory genes, causes premature aging syndromes5. 
By contrast, more subtle inter-individual variation in TL has been 
associated with the risk of certain cancers, coronary artery disease 
and other common age-associated adult conditions6–8. Although 
there has been much interest in a shorter TL as a biomarker of older 
biological age9, it is now apparent that the relationship between 
TL and disease risk is complex, as both shorter TL and longer TL 
have been associated with higher risks of different age-associated 
diseases4,10–12. Population biobanks afford opportunities to provide 
insight into the genetic architecture of TL and its links with bio-
medical phenotypes. Progress has been limited, however, because 
most biobanks have not been able to combine large-scale TL mea-
surement, detailed genomic characterization, extensive biomedical 
phenotyping and exceptional statistical power.
Here we interrogate a powerful population resource of periph-
eral leukocyte TL (LTL) measurements, a practical measure of TL 
that correlates well with TL across different tissues13 within indi-
viduals, that we created in 472,174 well-characterized participants 
in the UK Biobank (UKB)14,15. We increase knowledge of the genetic 
architecture of LTL several-fold, including identification of multiple 
new rare and lower-frequency variants associated with LTL. Using 
the principle of Mendelian randomization (MR), we find evidence 
to support causal roles for LTL with multiple physiological traits 
and diverse diseases. We also estimate that people with shorter LTL 
have a lower life expectancy.
Results
Genetic determinants of TL. We used an established quantitative 
PCR assay to obtain LTL measurements in 472,174 UKB participants, 
undertook multiple quality checks to control and adjust for techni-
cal factors, and confirmed associations with known LTL-associated 
phenotypes such as age, sex and ethnicity, as detailed elsewhere15. 
We also made paired LTL measurements from DNA taken at two 
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Telomeres, the end fragments of chromosomes, play key roles in cellular proliferation and senescence. Here we characterize 
the genetic architecture of naturally occurring variation in leukocyte telomere length (LTL) and identify causal links between 
LTL and biomedical phenotypes in 472,174 well-characterized UK Biobank participants. We identified 197 independent sentinel 
variants associated with LTL at 138 genomic loci (108 new). Genetically determined differences in LTL were associated with 
multiple biological traits, ranging from height to bone marrow function, as well as several diseases spanning neoplastic, vascu-
lar and inflammatory pathologies. Finally, we estimated that, at the age of 40 years, people with an LTL >1 s.d. shorter than the 
population mean had a 2.5-year-lower life expectancy compared with the group with ≥1 s.d. longer LDL. Overall, we furnish new 
insights into the genetic regulation of LTL, reveal wide-ranging influences of LTL on physiological traits, diseases and longevity, 
and provide a powerful resource available to the global research community.
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time points (mean interval: 5.5 years) in 1,351 participants to 
enable the calculation of, and correction for, regression dilution 
(Methods)15. Using standard genome-wide association analyses and 
exact joint conditional modeling in 464,716 participants with data 
available on 19.4 million imputed variants (minor allele frequency 
(MAF) ≥ 0.1%; Methods and Supplementary Fig. 1), we identified 
197 independent associations for LTL (Supplementary Table 1) 
exceeding a genome-wide significance threshold of P < 8.31 × 10−9 
(Methods). This threshold was set to account for the inclusion of 
low-frequency variants in the analysis16. The sentinel variants were 
located within 138 genomic loci (>500 kb between sentinels), of 
which 108 were new (>1 Mb from a previously reported sentinel) 
and 30 were previously reported at genome-wide significance or a 
false-discovery rate (FDR) of <5% (Fig. 1a, Supplementary Table 
1, Extended Data Fig. 1 and Supplementary Data)3,4,17. Collectively, 
the 197 variants explained 4.54% of the variance in LTL. In total, 
714 independent variants—the majority of which are new—were 
associated with LTL at an FDR threshold of <1% (Supplementary 
Table 2), increasing the amount of variance explained to 5.64%. The 
estimated heritability for LTL explained by all variants genome-wide 
was 8.1% (s.d. = 0.26).
Twenty of the genome-wide significant sentinel variants 
identified here for the first time (Supplementary Table 1) were 
lower-frequency variants (MAF < 1%), including new association 
signals at several known loci (including TERT1, TERF1 and RTEL1) 
and new loci (such as EXOSC10, SMC4 and SRSF6). The estimated 
effects of the sentinel variants were generally modest—that is, 
<0.2 s.d. per allele (Fig. 1b,c). Most of the loci with the strongest 
evidence for association (P < 1 × 10−50) had been previously iden-
tified, but two are new (Extended Data Fig. 1 and Supplementary 
Table 1): one is on the X chromosome, which was not analyzed in 
previous genome-wide association studies (GWAS), and the other, 
rs334 in HBB, is a variant known to cause sickle cell disease, which 


































2 3 4 5 6 7 8 9 10 11
Chromosome
12 13 14 15 16 17 18 19 20 2122 X
b c
Fig. 1 | Conditionally independent genome-wide significant hits. a, Manhattan plot curtailed at P < 1 × 10−50. We highlight the regions containing our 197 
sentinel variants that are genome-wide significant (P < 8.31 × 10−9; horizontal dashed reference line) in the exact joint conditional model (Supplementary 
Table 1). We defined the region as known (blue) if a previous variant within 1 Mb of our sentinel has been reported at either genome-wide significance or 
at an FDR threshold of <5%. Regions were considered new (red) if a variant within 1 Mb of our sentinel that reached genome-wide significance was not 
previously identified. Non-significant variants are shown in either light or dark gray on alternate chomosomes. b, The estimated effect sizes (beta) against 
the P value from the GWAS analysis. c, Estimated effect sizes for the minor allele (beta) against the MAF from all participants in the GWAS.
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HBB was used as a control gene in our LTL assay, the fidelity of 
its apparent association with LTL was investigated in further analy-
ses, which strongly suggested that this is an artifactual association 
(Supplementary Note and Supplementary Fig. 2). This locus was, 
therefore, removed from further analyses; we advise caution in the 
use of this control gene in future studies of LTL, especially those 
involving participants of African ancestry. Except for rs334, none of 
the other associations were driven by inclusion of individuals with 
non-European ancestry (Supplementary Table 1). We also inves-
tigated the extent to which the technical effect of rs334 explained 
the observed difference in LTL between participants of Black and 
White ethnicity (as defined by the UKB), which we have reported 
elsewhere15. Although, as expected, removal of carriers of the rs334 
minor allele attenuated the difference in LTL between participants 
of Black and White ethnicity, the participants of Black ethnicity still 
had significantly longer LTL than the participants of White ethnic-
ity (Supplementary Note).
Combining information on gene function, variant annotations 
and colocalizing expression quantitative trait loci (eQTLs; Methods, 
Supplementary Note and Supplementary Tables 3–6), we were able 
to prioritize likely causal genes at 114 (83%) of the loci we discovered. 
Many biological candidates were supported by functional predic-
tions and gene expression evidence, including strong eQTL support 
for TEN1, STN1 and RPA2 (Fig. 2 and Supplementary Tables 4–6). 
Genes with known roles in telomere regulation were found in 44 loci, 
including genes encoding components of the SHELTERIN (ACD 
(TPP1), TERF1, TERF2 and POT1) and CST (SNT1 (OBFC1), TEN1 
and CTC1) complexes, which act to cap the end of the telomere, 
suppressing inappropriate activation of the DNA-damage response 
and regulating telomerase processivity (Fig. 3)18. Components of 
the alternative lengthening of telomeres pathway (ATRX, PML and 
SLX4) were also among the new loci as well as genes encoding fac-
tors that post-translationally modify key telomere proteins, includ-
ing UPS7, which encodes a protein that deubiquitinates both POT1 
and ACD19,20. Genes within both known (TERC, TERT and NAF1) 
and new (DKC1, TEP1, SMG6, SHQ1, NOLC1 and RUVBL1) loci 
encode core components of proteins that regulate the assembly and 
activity of telomerase (Supplementary Note)21–24. Before telomerase 
assembly, TERC undergoes complex processing25. Genes involved in 
TERC stability, intracellular trafficking and processing were found 
in known (SMUG1) and new (PARN, TENT4B (PAPD5), TGS1 
and WRAP53) loci, including those associated with the RNA exo-
some (EXOSC6, EXOSC9, EXOSC10, DIS3 and ZCCHC8; Fig. 3 and 
Supplementary Note)25–28.
Other genes of interest in new loci are involved in DNA rep-
lication, recombination and repair, components of which have 
established roles in telomere maintenance29. Two new loci 
harbor components of the Replication protein A complex (RPA1  
and RPA2), which is recruited to telomeres during DNA rep-
lication30. The complex is later removed in a process involv-
ing hnRNPA1 (within the SMUG1 locus) and replaced by POT1 
(ref. 31). DNA double-strand-break repair genes with known roles 
in telomere regulation were also observed (SLX4, MCM4 and 
SAMHD1)32,33. Two other genes highlighted as likely to be causal are 
POLI and POLN. Neither is known to have a direct role in telomere 
maintenance; however, other DNA polymerases that are involved 
in translesion repair function in the alternative lengthening of telo-
meres pathway34, suggesting plausible roles for these polymerases in 
controlling TL.
To provide more evidence for the candidacy of our prioritized 
genes, we investigated whether rare (<0.1% MAF) protein-altering 
variants in these genes were associated with LTL using gene-based 
tests (Supplementary Note). The aggregated scores for eight genes 
(RTEL1, TERF1, TERT, ATM, PARN, SAMHD1, POT1 and CTC1) 
were significantly associated with LTL after Bonferroni correction 
(Supplementary Table 7). The directions of association with LTL for 
the individual variants included in this analysis are consistent with 
the known biological functions of these genes in telomere regula-
tion (Supplementary Table 8 and Supplementary Note). For exam-
ple, rare protein-truncating/altering variants throughout RTEL1 
were mostly associated with a shorter LTL, consistent with data sug-
gesting that the full-length RTEL1 protein is required to facilitate 
telomere elongation by telomerase35.
To identify potentially new pathways responsible for TL regula-
tion, we tested for over-representation of prioritized genes in known 
biological processes (Methods). As expected, the most significantly 
associated pathways identified were related to the regulation of 
telomere maintenance. Other enriched pathways, represented by 
multiple Gene Ontology biological processes, included box H/
ACA snoRNP assembly and snoRNA 3′-end processing, highlight-
ing key components of TERC regulation within the associated loci. 
Extending our previous identification of the relevance of nucleo-
tide metabolism to LTL3, the current analysis more specifically pri-
oritized pyrimidine metabolism through multiple associated Gene 
Ontology processes (Supplementary Table 9).
An additional motivation for undertaking the GWAS was to cre-
ate genetic instruments to enable causal inference analysis of LTL 
with biomedical phenotypes. To minimize the inclusion of corre-
lated variants or those showing extensive pleiotropy in these analy-
ses, we filtered the 197 sentinel variants further (Methods), yielding 
130 conditionally independent, uncorrelated and ‘non-pleiotropic’ 
genome-wide significant instruments used in the MR analyses 
described below (Supplementary Table 1).
Influences on biomedical traits. Partly guided by previous reports 
(Supplementary Table 10), we prioritized 93 biomedical traits avail-
able in the UKB, comparing MR results with observational results 
based on LTL levels corrected for the observed regression-dilution 
ratio of approximately 0.68 (abbreviated as ‘usual LTL’; 
Supplementary Note). We focused mainly on continuous traits 
related to body shape and size, cardiorespiratory function, repro-
ductive health, physical fitness, bone marrow function, cognition, 
bone health, and liver and endocrine function (Supplementary Table 
10). After Bonferroni correction, 18 of the traits were significantly 
associated in the same direction with both genetically determined 
LTL and usual LTL (Fig. 4 and Supplementary Table 10). Genetically 
determined LTL was more strongly related to most traits than usual 
LTL, probably reflecting lifelong influences (Supplementary Table 
10). However, for all traits, LTL explained only a small proportion 
of the variance (<0.5%). For an additional 12 traits, we found nomi-
nally significant associations (P < 0.05) with genetically determined 
LTL, with most of these traits showing significant and concordant 
associations with usual LTL (Fig. 4 and Supplementary Table 10). 
A further 38 traits showed Bonferroni-significant observational 
associations but no associations with genetically determined LTL 
(Extended Data Fig. 2 and Supplementary Table 10). A lack of con-
cordance for these traits could reflect either residual bias in obser-
vational analyses or limited statistical power in the MR analyses.
Overall, our findings demonstrate that variation in the LTL 
affects a wide range of biological and physiological traits spanning 
multiple body systems. We confirmed associations of genetically 
determined longer LTL with higher blood pressure36 and identi-
fied new associations with circulating biomarkers of metabolic 
and endocrine function, including higher insulin-like growth 
factor 1 (IGF-1) and lower sex hormone-binding globulin (Fig. 4 
and Supplementary Table 10). IGF-1 is a growth hormone asso-
ciated with pubertal growth in height. Adjusting for IGF-1 lev-
els attenuated the association between height and longer usual 
LTL (beta = 0.011 (0.010, 0.013); P = 1.91 × 10−27), suggesting 
that IGF-1 may partly mediate the relationship between LTL and 
height. Notably, we observed associations between genetically deter-
mined LTL and multiple hematological traits (Fig. 4). Associations 
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of longer LTL with higher counts of neutrophils, platelets and eryth-
rocytes but lower counts of lymphocytes and eosinophils (Fig. 4  
and Extended Data Fig. 2) suggest an effect of LTL variation on 
lineage fate at the lympho-erythromyeloid progenitor level37. The 
contrasting associations of LTL with erythrocyte count versus 
erythrocyte size and hemoglobin content may reflect a primary 
effect on the maintenance of red blood cell mass38. However, for 
platelets, longer LTL was associated not only with a higher count 
but also with larger volume, resulting in an increased platelet mass 
(Fig. 4 and Extended Data Fig. 2), consistent with recent observa-
tions that megakaryocytes—platelet precursor cells that reside in 
the bone marrow—originate directly from megakaryocyte-primed 
hematopoietic stem cells39 and not from a precursor cell clonally 
related to erythroid precursors.
Influences on disease outcomes. To identify causal links between 
LTL and disease outcomes using MR analyses, we prioritized 
123 diseases defined using information available in the UKB 
(Supplementary Table 11 and Supplementary Note). We compared 
the results from the MR analyses with observational Cox regres-
sion analyses of incident cases. After Bonferroni correction, 16 of 
the diseases were significantly associated with genetically deter-
mined LTL (Fig. 5 and Supplementary Table 12). We confirmed 
associations of longer genetically determined LTL with lower risk 
of coronary artery disease as well as with a higher risk of several 
organ-specific cancers, including prostate, melanoma, thyroid and 
kidney, and genitourinary tumors (uterine polyps and fibroids)3,11. 
We found new associations of longer genetically determined LTL 















































































































































































































































































































































































Fig. 2 | identification of eQTL signals at genome-wide significant loci. Circular representation of colocalized eQTLs across 48 tissues in GTEx. Strong 
colocalization is shown as a colored tile, with the color determined by the degree of tissue specificity of colocalization: ubiquitous, ≥33 tissues; 
tissue-group specific, 17–32 tissues; multiple tissues, 2–16 tissues; and single tissue, one tissue. Tissues are represented numerically with full details in 
Supplementary Table 5. Genes are labeled using HGNC gene symbols. Tissues are ordered by GTEx tissue groupings, and genes are ordered by hierarchical 
clustering of the data, which groups genes with a similar colocalization pattern.
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or hematopoietic tissues) and endometriosis (the growth of endo-
metrial tissue outside of the uterus). Results were consistent across 
sensitivity analyses, suggesting robustness to horizontal pleiotropy 
(Supplementary Figs. 3 and 4).
Of the 16 diseases that were significantly associated with geneti-
cally determined LTL, 12 were also Bonferroni-corrected or nomi-
nally (P < 0.05) significantly associated with usual LTL in the same 
direction (Fig. 5). For most conditions causally linked to LTL, we 
identified approximately log-linear dose–response relationships of 
usual LTL with incident outcomes (Supplementary Figs. 5 and 6). 
As for biomedical traits, we found that genetically determined LTL 
was more strongly related to diseases than usual LTL (Fig. 5). For 
two conditions (leukemia and hypertension), we observed signifi-
cant results in opposing directions for the MR and observational 
analyses (Fig. 5). For leukemia, we observed a U-shaped association 
with usual LTL (Supplementary Fig. 5), which may represent dif-
ferent stages of the disease process within individuals before diag-
nosis. Hematopoietic stem cells with a longer TL are more likely to 
accrue somatic mutations that potentially lead to leukemic trans-
formation40, whereas subsequent high proliferation rates during 
clonal expansion and the resulting telomere attrition are consistent 
with the shorter TL in tumors noted in other observational stud-
ies41. For hypertension, it was probably due to residual bias in the 
observational analysis (Supplementary Fig. 7, Supplementary Table 
13 and Supplementary Note). We did not find evidence that blood 
pressure or plasma lipid levels (high-density lipoprotein cholesterol, 
low-density lipoprotein cholesterol and triglycerides) explained 
the association between shorter genetically determined LTL and a 
higher risk of coronary artery disease.
For an additional 16 diseases, we found nominally significant 
(P < 0.05) associations with genetically determined LTL (Fig. 
5). Of these, ten also had Bonferroni or nominally significant 
and concordant associations with usual LTL (Fig. 5), suggesting 
that future more powerful MR studies may strengthen the evi-
dence for causality. These included new associations with colorec-
tal cancer, liver cirrhosis, kidney stones and atopic dermatitis. 
For 26 diseases, we found Bonferroni-significant associa-
tions with usual LTL but non-significant associations with 
genetically determined LTL (Extended Data Fig. 3 and 
Supplementary Table 12). These findings could reflect either 
residual bias in the observational analysis or limited power in the 
MR analyses (Supplementary Note). Finally, for 65 diseases, we 
found no association in either the MR or observational analyses 
(Supplementary Table 12).
Influences on life expectancy. Given the causal links between LTL 
and multiple conditions—both in risk-increasing and risk-reducing 
directions—a relevant unresolved question is whether LTL has 
a net impact on life expectancy42–44. Using previously described 
public health modeling methods that draw on cause-specific 
mortality rates from the general population (Methods), we esti-
mated that men with telomeres that were >1 s.d. shorter than the 
population mean at the age of 40 years had a lower life expectancy 
compared with those with telomeres that were ≥1 s.d. longer by 
2.47 years (95% confidence interval (CI), 1.99–2.96; Fig. 6a); the 
corresponding estimates for women were very similar. These esti-
mated differences were sustained to the age of 65 years and gradu-
ally declined thereafter. Excess cardiovascular deaths accounted for 
13% and 9%, and cancer deaths 5% and 4%, of the survival differ-
ences in men and women, respectively, with most of the remainder 
due to other causes (Fig. 6b). Broadly similar results were observed 
in sensitivity analyses that involved different modeling assumptions 
(Supplementary Fig. 8).
Discussion
This study elucidates the polygenic basis and biomedical conse-
quences of LTL variation. In the most powerful genomic study so 
far, we implicate many new candidate genes, highlight the complex 
regulation of LTL and identify roles for TERC processing and pyrim-
idine metabolism. Using wide-angle analyses, we provide insight 
into the causal relevance of LTL to biological traits and diseases 


























Fig. 3 | Genes with known regulatory roles in telomere maintenance located within GWAS loci. Key components of telomere regulatory complexes found 
within genome-wide significant loci. Proteins encoded within GWAS loci are depicted in green, and those not found within GWAS loci are depicted in blue. 
We found the majority of components of core telomere binding complexes alongside many proteins involved in the formation and activity of telomerase. 
Note that not all components of the RNA exosome are shown.
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associations in the same set of participants. There is much interest 
in shorter TL as a target for pharmacological and other interven-
tions45,46. Two findings from our analyses provide insight into this 
issue. First, for coronary artery disease and most other conditions 
causally linked with a shorter LTL, we found continuous linear asso-
ciations—that is, no threshold above which LTL stops being associ-
ated with risk—indicating that any benefits could accrue across the 
range of TL. On the other hand, the observation that a longer LTL 
is causally associated with risk of several cancers—possibly because 
longer telomeres allow more cell divisions and clonal expansion 
after first-hit cancer mutations, thereby increasing the likelihood of 
second-hit mutations that drive oncogenic transformation47—high-
lights the complexity of TL as a therapeutic target. In addition, our 
finding of a U-shaped relationship between usual LTL and leukemia 
potentially explains the dual character of the association observed 
between TL and cancers. The same mechanism may also exist for 
solid tumors, namely a longer TL predisposes individuals to an 
increased risk of cancer (as also supported by the MR analysis), 

































































































































–0.4 –0.2 0 0.2 0.4
Beta (95% CI) per s.d. longer LTL
MR P < 0.05 P < 5.4 × 10–4
Observational P ≥ 0.05 P < 0.05 P < 5.4 × 10–4
Fig. 4 | Biomedical traits associated with genetically determined LTL. Biomedical trait MR associations from the inverse-variance-weighted analysis 
(Supplementary Table 10) are shown with a solid square and expressed in beta per s.d. longer genetically determined LTL. Observational associations are 
shown with an empty circle and expressed in beta per s.d. longer usual LTL from linear regression models.
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Our results suggest that, despite the directionally opposing asso-
ciations of LTL with different diseases, a shorter LTL at the age of 
40 years is on average associated with a decrease in life expectancy 
of approximately 2.5 years. For comparison, the estimated reduc-
tions in life expectancy from long-term cigarette smoking and hav-













































































































































































0.60 1.0 2.0 3.0
OR or HR (95% CI) per s.d. longer LTL
MR P < 0.05 P < 4.1 × 10–4
Observational P ≥ 0.05 P < 0.05 P < 4.1 × 10–4
Fig. 5 | Diseases associated with genetically determined LTL. Disease MR associations from the inverse-variance-weighted analysis (Supplementary 
Table 12) are shown with a solid square and expressed as odds ratio (OR) per s.d. longer genetically determined LTL. Observational associations are shown 
with an empty circle and expressed as the hazard ratio (HR) per s.d. longer usual LTL from Cox proportional hazards models. n refers to the number of 
cases for each condition.
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Overall, our study provides a major resource for understanding the 
relevance of LTL to many complex diseases and traits.
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Fig. 6 | Years of life lost using uK 2015 mortality rates. a,b, The number of years of life lost were estimated by applying HRs for cause-specific mortality 
calculated from UKB data (specific to age-at-risk and stratified by sex) to population mortality rates for the United Kingdom during 2015 (by sex and 
5-year age groups). Data are presented for four standardized LTL groups: group 1, >1 s.d. below the mean; group 2, ≤1 s.d. below the mean; group 3, <1 s.d. 
above or equal to the mean; and group 4, ≥1 s.d. above the mean) from 40 to 95 years of age. Group 4 was used as the reference group. Data are shown for 
males and females separately. This was performed for all-cause (a) and disease-specific (b) mortality. The UKB data included 458,309 participants and 
28,345 deaths (comprising 5,984 vascular deaths, 14,916 cancer deaths, 7,244 non-vascular, non-cancer deaths and 201 deaths of unknown causes).
NATuRE GENETiCS | VOL 53 | OCTOBER 2021 | 1425–1433 | www.nature.com/naturegenetics1432
ArticlesNature GeNetics
 33. Majerska, J., Feretzaki, M., Glousker, G. & Lingner, J. Transformation-induced 
stress at telomeres is counteracted through changes in the telomeric proteome 
including SAMHD1. Life Sci. Alliance 1, e201800121 (2018).
 34. Garcia-Exposito, L. et al. Proteomic profiling reveals a specific role for 
translesion DNA polymerase η in the alternative lengthening of telomeres. 
Cell Rep. 17, 1858–1871 (2016).
 35. Awad, A. et al. Full length RTEL1 is required for the elongation of the 
single-stranded telomeric overhang by telomerase. Nucleic Acids Res. 48, 
7239–7251 (2020).
 36. Demanelis, K., Tong, L. & Pierce, B. L. Genetically increased telomere length 
and aging-related traits in the U.K. Biobank. J. Gerontol. A 76, 15–22 (2021).
 37. Rodriguez-Fraticelli, A. E. et al. Clonal analysis of lineage fate in native 
haematopoiesis. Nature 553, 212–216 (2018).
 38. Astle, W. J. et al. The allelic landscape of human blood cell trait variation and 
links to common complex disease. Cell 167, 1415–1429 (2016).
 39. Choudry, F. A. et al. Transcriptional characterization of human 
megakaryocyte polyploidization and lineage commitment. J. Thromb. 
Haemost. 19, 1236–1249 (2021).
 40. Brown, D. W. et al. Genetically predicted telomere length is associated with 
clonal somatic copy number alterations in peripheral leukocytes. PLoS Genet. 
16, e1009078 (2020).
 41. Barthel, F. P. et al. Systematic analysis of telomere length and somatic 
alterations in 31 cancer types. Nat. Genet. 49, 349–357 (2017).
 42. Bakaysa, S. L. et al. Telomere length predicts survival independent of genetic 
influences. Aging Cell 6, 769–774 (2007).
 43. Deelen, J. et al. Leukocyte telomere length associates with prospective 
mortality independent of immune-related parameters and known genetic 
markers. Int. J. Epidemiol. 43, 878–886 (2014).
 44. Steenstrup, T. et al. Telomeres and the natural lifespan limit in humans. Aging 
9, 1130–1142 (2017).
 45. Jaskelioff, M. et al. Telomerase reactivation reverses tissue degeneration in 
aged telomerase-deficient mice. Nature 469, 102–106 (2011).
 46. Farzaneh-Far, R. et al. Association of marine omega-3 fatty acid levels with 
telomeric aging in patients with coronary heart disease. JAMA 303, 250–257 
(2010).
 47. Aviv, A., Anderson, J. J. & Shay, J. W. Mutations, cancer and the telomere 
length paradox. Trends Cancer 3, 253–258 (2017).
 48. Doll, R., Peto, R., Boreham, J. & Sutherland, I. Mortality in relation to 
smoking. Brit. Med. J. 328, 1519 (2004).
 49. Sattar, N. et al. Age at diagnosis of type 2 diabetes mellitus and associations 
with cardiovascular and mortality risks. Circulation 139, 2228–2237 (2019).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in 
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons 
Attribution 4.0 International License, which permits use, sharing, adap-
tation, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, provide a link to 
the Creative Commons license, and indicate if changes were made. The images or other 
third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons license and your intended use is not permitted by statu-
tory regulation or exceeds the permitted use, you will need to obtain permission directly 
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2021
NATuRE GENETiCS | VOL 53 | OCTOBER 2021 | 1425–1433 | www.nature.com/naturegenetics 1433
Articles Nature GeNetics
Methods
LTL measurements. The measurement of LTL in the UKB participants and 
the extensive quality checks and adjustment for technical factors are detailed 
elsewhere15. For the analyses presented in this paper, we included all participants 
with the LTL measured from a UKB baseline sample, where there was no mismatch 
in self-reported and genetic sex (n = 472,174; data-freeze, December 2020). The 
LTL values were log-transformed and Z-standardized for all analyses.
GWAS. We used imputed genotypes available in the UKB2 for the GWAS. To 
ensure quality, we restricted the analysis to variants with a MAF of ≥0.1% (where 
imputation accuracy is greatest) and an INFO score of ≥0.3. We tested 19.4 million 
variants using the BOLT-LMM package, adjusting for age, sex, array and the first 
ten principal components (PCs). The analysis was run separately for chromosome 
23, where males were coded as 0/2.
Conditional association analyses. To identify independently associated variants 
within loci, we adopted a two-stage approach to conditional analyses. We first 
used the summary statistics for variants meeting a threshold of P < 1 × 10−6 
from the GWAS to perform a joint conditional analysis using GCTA (version 
1.25.2; see Supplementary Note). We set a genome-wide significance threshold at 
P < 8.31 × 10−9, which has been suggested as an appropriate threshold for GWAS 
studies incorporating lower-frequency and rare variants (MAF > 0.1%)16. All 
variants with P < 8.31 × 10−9 were then taken forward to stage two. In the second 
stage, we performed exact joint modeling using BOLT-LMM, where we adjusted 
for all other variants from stage one, age, sex, genotype array and the first ten PCs 
in the model. All variants emerging from this analysis with P < 8.31 × 10−9 were 
considered to be conditionally independent at the genome-wide significance level.
Variance explained by the genetic variants. To estimate the variance explained 
by all conditionally independent genome-wide significant variants, we extracted 
them from the imputed genetic data, scored by allele dosage. We only included 
participants that had both autosome and X-chromosome data. To account for 
familial correlation, we randomly excluded one participant from each related pair, 
where a pair was related if the kinship coefficient (K) was >0.088, estimated using 
genetic relatedness2. A linear regression adjusted for age, sex, array and the first 
ten genetic PCs was run to estimate the model variance explained (R2). A second 
model including all genetic variants was then run to estimate the full model R2 with 
the difference in the model R2 used to determine the variance explained by the 
genetic variants.
To determine variants that passed an FDR50, we estimated the P value 
equivalent to a q-value of <0.01 as FDR_P < 3.9 × 10−5. All variants from the 
GWAS with P < 1 × 10−4 were tested using GCTA (Supplementary Note) to identify 
conditionally independent variants that passed our FDR_P threshold. These were 
then clumped using PLINK to include only independent variants not in linkage 
disequilibrium (R2 < 0.01). The remaining variants were then extracted and 
modeled as above to estimate the variance explained by the FDR set.
SNP-based heritability. The SNP-based heritability was estimated from the GWAS 
summary statistics using the BLD-LDAK model implemented in the SumHer 
package using the precomputed tagging file for individuals from the UKB51.
Identification of potential causal variants. To identify putative causal variants 
allowing for multiple putative causal variants within a locus, we performed a 
shotgun stochastic search using FINEMAP v1.4 (refs. 52,53). For each locus, we 
calculated the posterior probability of the causal configurations and report the 
most probable set. First, we defined a region to contain all variants within a 1 Mb 
window centered on each sentinel SNP. We identified the top causal variant for 
each region and identified all regions harbored within multiple sentinel GWAS 
loci. Initially, we specified there to be only one causal variant. We then grouped the 
regions in multi-lead-SNP GWAS loci by locus (containing k lead SNPs within the 
1 Mb region). We then allowed for a maximum of i causal variants (i = k + 3). If the 
maximum posterior probability (PPicvar) for having i causal variants in the region 
was ≤95%, we selected the causal configuration and then generated credible sets. 
If PPicvar > 95%, we further allowed for a maximum of j causal variants (j = i + 3) 
and selected the causal configuration that had the largest PPicvar closest to 95%. 
However, if PPicvar was very low, the single causal configuration was selected 
(Supplementary Table 14).
Identification of potential causal genes. To identify potential causal genes within 
the associated loci, we identified genes with known roles in telomere regulation 
(candidate genes) and used information from variant annotation in the eQTL 
colocalization analyses. Functional annotation for all variants identified within 
the 95% credible sets produced from fine-mapping was collected using VEP54 
(Supplementary Note).
To investigate whether the variants included within the 95% credible sets for 
each locus identified using FINEMAP shared a common causal variant with eQTL 
signals, we conducted colocalization analyses using COLOC55. Transcriptomic 
data were obtained from GTEx.v7 for genes with a q-value of <0.5 for all 48 
tissues56. The COLOC method uses an approximate Bayes factor with both GWAS 
and eQTL summary statistics and regional linkage disequilibrium structure to 
estimate the posterior probabilities for five scenarios (PP0, PP1, PP2, PP3 and 
PP4). A high PP4 indicates evidence of a shared single causal variant. For each 
of the GWAS signals, we defined a 1 Mb region centered on the sentinel variant 
to test for colocalization using the COLOC R package (https://cran.r-project.
org/web/packages/coloc/vignettes/vignette.html). We defined strong evidence of 
colocalization as PP3 + PP4 ≥ 0.99 and PP4/PP3 ≥ 5, and suggestive evidence as 
PP3 + PP4 ≥ 0.90 and PP4/PP3 ≥ 3, as previously described4,57.
Genes were prioritized on strength of evidence in the following order: biological 
candidate > high-impact annotation > moderate-impact annotation > strong 
evidence of colocalization > suggestive evidence of colocalization. Where expression 
of multiple genes was associated with our causal variants, we prioritized candidacy 
based on the number of tissues with evidence. To run downstream pathway analysis 
and gene-based tests where it was not possible to prioritize a gene at a locus, we 
substituted the nearest gene to the most significantly associated causal variant. 
Conversely, where it was not possible to prioritize a single gene from several with 
evidence, multiple genes were taken forward.
Pathway analysis. We tested our list of prioritized or nearest genes for statistical 
over-representation (Fisher’s exact test) in PANTHER58. Pathways within the 
Gene Ontology biological process complete annotation set were considered to be 
significantly over-represented at an FDR q-value of <0.05.
Gene-based tests. We removed noncoding RNAs, pseudogenes and poorly 
annotated new transcripts from the prioritized genes identified in the GWAS loci. 
We then extracted rare and ultra-rare variants (MAF < 0.1%) within the exon 
boundaries of these genes from the UKB exome sequencing data59. Protein-altering 
variants were scored as predicted high-confidence loss-of-function and ultra-rare 
missense variants based on annotation obtained from VEP using the VEP LOFTEE 
plugin (Supplementary Note)54,60. For each participant, the gene-specific score was 
obtained by aggregating the variant scores, capped at one (Supplementary Note). 
We tested the association between the gene-specific scores and LTL using linear 
regression implemented in R v.4.0.1, adjusting for age and sex. To support this, we 
ran single-variant analyses of the rare variants using PLINK v1.9, also adjusting for 
age and sex.
Genetic instruments for MR analysis. Starting with the 193 sentinel variants 
located on the autosomes, we removed correlated variants from loci with more 
than one conditionally independent variant by removing those with r2 > 0.01 using 
PLINK clumping with linkage disequilibrium based on the same randomly selected 
UKB sample as for the conditional association analysis. We removed the HBB locus 
due to potential technical artifacts (Supplementary Note). To remove potentially 
pleiotropic loci, we investigated the remaining 147 variants for association with 
multiple traits and phenotypes using previously curated data61. For each variant, 
we derived the number of associations within different biological domains and 
defined evidence of pleiotropy as associations within at least three different 
domains. This led to the selection of 130 conditionally independent, uncorrelated 
and non-pleiotropic genome-wide significant instruments that we used for all MR 
analyses (Supplementary Table 1).
Mendelian randomization. With our genetic instruments for LTL, we performed 
single-sample univariable MR using two-sample methods that have been shown 
to be robust in large-scale biobanks62. We used (1) the inverse-variance-weighted 
method for LTL based on all 130 independent and uncorrelated variants associated 
with LTL63, (2) MR-Egger regression to estimate unmeasured pleiotropy64, (3) 
weighted median estimator to assess the robustness to extreme SNP–outcome 
associations65 and (4) a contamination-mixture method to explore potential 
presence of multiple pathways66. To account for between-variant heterogeneity, 
we used multiplicative random-effects models in all analyses and quantified 
heterogeneity using the I-squared statistic from MendelianRandomization package 
v. 0.5.0 (https://CRAN.R-project.org/package=MendelianRandomization).
Analysis of biomedical traits. To assess the influence of LTL on biomedical 
traits, we were partly guided by previous reports (Supplementary Table 12) in our 
prioritization of 93 biomedical traits, focusing only on continuous and binary 
outcomes. Continuous traits were first winsorized at the 0.5% and 99.5% percentile 
values to account for potentially influential outliers. After checking the distribution 
of the winsorized traits using histograms, natural logarithm transformations were 
applied to non-normally distributed traits where appropriate. All continuous 
biomedical traits were then scaled to the Z-standardized normal distribution. To 
account for familial correlation, we randomly excluded one from each related pair, 
where a pair was related if K > 0.088.
We used MR to investigate causal associations of LTL with biomedical traits. 
To estimate the genetic associations for each of our 130 genetic instruments with 
each biomedical outcome, we performed logistic regression for binary traits and 
linear regression for continuous traits, adjusting for age, sex, array and the first five 
genetic PCs using SNPTEST67. We then used MR to investigate causal associations 
of LTL with biomedical traits and ran MR sensitivity analyses (Supplementary  
Figs. 9 and 10).
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Observational analyses were conducted to investigate the association between 
LTL and biomedical traits. The Z-standardized LTL was used as the predictor of 
interest to provide effect-size estimates for an increase in LTL of 1 s.d. Continuous 
traits were assessed using linear regression models, whereas logistic regression 
models were used for binary traits. All regression models were adjusted for age, 
sex, ethnic group (defined by the UKB as Asian, Black, Chinese, Mixed, Other and 
White) and white blood cell (WBC) count, as proposed elsewhere15. To correct for 
measurement error and within-person variability in LTL over time, observational 
associations of LTL with traits and diseases were corrected for the observed 
regression-dilution ratio of 0.68, as detailed elsewhere15. Observational associations 
relate to usual LTL, unless otherwise specified. The magnitude of association was 
estimated using a partial R2, calculated as the difference between the full model R2 
and the model R2 leaving LTL out.
To assess nonlinear associations between LTL and the traits, a quadratic term 
(the squared value of the LTL) was included in separate models in addition to LTL, 
age, sex, ethnicity and WBC. We further assessed the nonlinear associations of LTL 
with various traits by fitting fractional polynomial models (Supplementary Figs. 
11 and 12) adjusted for age, WBC count, sex and ethnic group. The best fitting 
fractional polynomial model, selected using P < 0.05 as evidence for selecting more 
complex nonlinear functions, was used to plot the continuous shape of association 
relative to the reference value of zero68. In further supplementary analyses, we 
calculated adjusted HRs by deciles of LTL and plotted them against the mean 
standardized LTL within deciles.
Analysis of disease outcomes. We identified 123 diseases (Supplementary 
Table 8) using a slightly modified version of the strategy reported previously4 
(Supplementary Note). The selection of diseases aimed to balance the needs for 
clinical relevance (for example, avoiding overlapping outcomes—that is, coronary 
artery disease and myocardial infarction), detail (to cover diseases with different 
physiopathology) and statistical power. We conducted power calculations due to the 
large differences in disease prevalence using the ‘powerLogisticCon’ function from 
the R package powerMediation69. These power calculations (Supplementary Fig. 13) 
showed that all outcomes had at least 60% power to detect an OR of 1.1 at the 5% 
level of significance. Around 75% of our disease outcomes, based on prevalence, had 
>99% power to detect an OR of 1.1, with 60% of our outcomes having >99% power 
to detect an OR of 1.05. To account for familial correlation, we randomly excluded 
one participant from each related pair, where a pair was related if K > 0.088.
Using a combination of prevalent and incident diseases (Supplementary Note), 
we estimated the genetic associations with each disease outcome using logistic 
regression. We then performed an MR using these estimates as for the biomedical 
traits described earlier. For the observational associations, time-to-event analyses 
were conducted between Z-standardized LTL and incident disease using Cox 
proportional hazards models, stratified by sex and ethnicity and adjusted for age 
and WBC count. For this analysis, participants with prevalent disease at baseline 
were excluded. To test the proportional hazards assumption, we fit an interaction 
term between LTL and time. For any deviations from proportional hazards 
(time interaction P < 0.05), we estimated the HRs at baseline and at 10 years via 
linear combination. We performed these analyses using the survival (https://
CRAN.R-project.org/package=survival) and greg (https://CRAN.R-project.org/
package=Greg) packages in R.
To investigate reasons for any discrepancies between the MR and observational 
results, we performed MR analyses using only incident disease outcomes and 
observational analyses using logistic regression with incident and prevalent data. 
The shapes of associations were assessed using fractional polynomials70 with Cox 
regression models adjusted for age and WBC and stratified by sex and ethnic 
group. The best fitting model was selected in the same way as for the biomedical 
trait analysis.
LTL and longevity. Details of the methods used to estimate differences in life 
expectancy have been previously described71, with further specific information 
regarding the modeling for LTL provided in the Supplementary Note. Briefly, 
estimates of cumulative survival from the age of 40 years were calculated among 
four groups of Z-standardized measured LTL (group 1, >1 s.d. below the mean; 
group 2, ≤1 s.d. below the mean; group 3, <1 s.d. above or equal to the mean; 
and group 4, ≥1 s.d. above the mean, the reference group) by applying HRs for 
cause-specific mortality calculated from the UKB study (specific to age-at-risk 
and stratified by sex) to population mortality rates for the United Kingdom 
and European Union in 2015 (by sex and 5-year age groups). Calculations were 
performed giving specific consideration to interpreting estimated differences 
in life expectancy between groups 1 (that is, shorter telomeres) and 4 (that is, 
longer telomeres) from the age of 40 years. Analyses involved Stata version 14.0 
(StataCorp) with two-sided P values and used a significance level of P < 0.05.
Ethics. The UKB has ethical approval from the North West Centre for Research 
Ethics Committee (application 11/NW/0382), which covers the United Kingdom. 
The UKB obtained informed consent from all of the study participants. Full details 
can be found at https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/
about-us/ethics. The generation and use of the data presented in this paper was 
approved by the UKB access committee under UKB application number 6077.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
Source data are accessible via application to the UKB. Summary statistics of the 
GWAS are available at https://figshare.com/s/caa99dc0f76d62990195.
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Extended Data Fig. 1 | Manhattan plot unrestricted by P value. We highlight our 197 sentinel variant regions that are genome-wide significant (P < 8.31 
× 10−9, horizontal dashed reference line) in the exact joint conditional model (Supplementary Table 1). We define the region as known (blue) if a previous 
variant within 1 Mb of our sentinel has previously been reported at genome-wide significance. We consider our other regions novel (red) as the first 
evidence of a variant within 1 Mb of our sentinel that reaches genome-wide significance.
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Extended Data Fig. 2 | Biomedical traits associated with usual LTL only. Mendelian randomization (MR) associations are shown with a solid square and 
expressed as beta per standard deviation (s.d.) longer genetically determined leukocyte telomere length (LTL) for the inverse-variance weighted (IVW) 
analysis. Observational associations are shown with an empty circle and expressed in beta per s.d. longer usual LTL from linear regression models. CI, 
confidence interval. Full data for each trait can be found in Supplementary Table 10.
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Extended Data Fig. 3 | Diseases associated with usual LTL only. Mendelian randomization (MR) associations are shown with a solid square and 
expressed in odds ratio (OR) per standard deviation (s.d.) longer genetically determined leukocyte telomere length (LTL). Observational associations are 
shown with an empty circle and expressed in hazard ratio (HR) per s.d. longer usual LTL from Cox proportional hazards models. CI, confidence interval. Full 
data for each disease can be found in Supplementary Table 12.
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